RiverVest Funds I, II & III RiverVest Fund IV Archer Seed Fund

14 Dec

Posted at 13:52h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAConforma Therapeutics discovered and developed drugs that inhibit heat shock protein 90 (HSP90) molecules, which are involved in protecting and supporting the growth of cancer cells across a range of tumor types,...

14 Dec

Posted at 13:51h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Lenexa, KSCyDex Pharmaceuticals, Inc. developed Captisol®, a drug delivery technology that can significantly improve the solubility, stability and bioavailability of active pharmaceutical ingredients. Captisol is a doughnut-shaped cyclodextrin molecule that holds a drug in...

14 Dec

Posted at 13:48h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAExcaliard Pharmaceuticals focused on the development of novel and innovative drugs for the amelioration of skin scarring and other fibrotic disorders. Its lead compound, EXC 001, was an antisense oligonucleotide drug targeting...

14 Dec

Posted at 13:37h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Houston, TXIDEV Technologies, Inc. developed the Supera™ stent for the treatment of peripheral artery disease. The use of interwoven, individual, flexible nitinol wires enables a unique combination of high compression resistance, low chronic outward...

13 Dec

Posted at 21:23h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CALumena developed a drug for the treatment of Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), two life-threatening pediatric liver diseases. If left untreated, these conditions can lead to liver failure...

13 Dec

Posted at 21:20h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Minneapolis, MNFounded in part by RiverVest, Lutonix developed the first FDA-approved drug-coated angioplasty balloon catheter that delivers paclitaxel to the arterial wall when used for the treatment of peripheral artery disease. Paclitaxel is an...

13 Dec

Posted at 21:17h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Rockville, MDIPO October 2013 (NASDAQ: MGNX)MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of...

13 Dec

Posted at 21:13h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAIPO July 2019 (NASDAQ: MIRM)Mirum was formed, with support from RiverVest, to develop the compound previously developed by Lumena (see Lumena discussion above).  After Takeda’s acquisition of Shire, the compound, now called...

13 Dec

Posted at 21:09h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAMpex Pharmaceuticals developed inhaled levofloxacin (brand name Quinsair), an antibiotic used for long-term lung infection treatment in people with cystic fibrosis. Levofloxacin is a well-known antibiotic that had been approved and prescribed...

13 Dec

Posted at 21:06h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAOtonomy works to bring new treatment options to patients with hearing and balance disorders. Otonomy’s technology enables drugs to reach targets effectively and safely within the protected inner ear. The company is...

13 Dec

Posted at 21:03h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Portsmouth, NHSalient Surgical developed the AquamantysTM system, which uses proprietary TranscollationTM technology that combines radiofrequency (RF) energy and saline to provide sealing of vascular tissue without the smoke and charring associated with competing methods....

13 Dec

Posted at 20:58h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Cleveland, OHSecurus Medical developed a device to provide clinicians a simple to use, real-time, noncontact, thermal map of body cavity tissue temperature, including in the esophagus during ablation procedures for treating atrial fibrillation, to...

13 Dec

Posted at 20:55h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Minneapolis, MNVelocimed developed multiple unique interventional cardiology products, including a proximal embolic protection device (Proxis™), a patent foramen ovale (“PFO”) closure device (PremereTM) and a directional catheter (VentureTM) for navigating tortuous vasculature. Each of...

13 Dec

Posted at 20:53h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Fort Worth, TXIPO June 2014, then acquired by AstraZeneca December 2015.ZS Pharma developed Lokelma, a drug to treat hyperkalemia, a serious condition characterized by elevated potassium levels in the blood associated with cardiovascular, renal...

13 Dec

Posted at 20:45h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Waltham, MASeQure Dx, Inc. is applying state-of-the-art genomics technologies for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Their core technologies, GUIDE-seq and ONE-seq, enable identification of all potential off-target...